profit from every $100 of sales.
$0$100
BioPharma Credit Ord
$0.99+0.41% today
+7.6% in 1 year
1-year low $0.891-year high $0.99
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $8.55 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What BioPharma Credit Ord sold, what it kept, and what it did with the cash.
Sales went from $184 million in 2022 to $132 million in 2025, with $130 million of profit last year.
SalesProfit
BioPharma Credit Ord handed back more cash to shareholders than it generated last year.
Buybacks $51M$110M
Free cash flow 2025$91M
Bought back its own shares$51M
Paid as dividends$110M
AI analysis
An AI analyst reads BioPharma Credit Ord's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 184 | 110 | 124 | 132 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – | |
| 182 | 108 | 122 | 130 | |
| 0.13 | 0.08 | 0.10 | – | |
| – | – | – | – | |
| – | – | – | – | |
| 99.0% | 98.2% | 98.2% | 98.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,364 | 1,357 | 1,200 | 1,168 |
| Cash | 121 | 86 | 6 | 13 |
| Total debt | – | – | – | – |
| Total liabilities | 27 | 16 | 18 | 18 |
| 1,337 | 1,341 | 1,182 | 1,151 | |
| 1,364 | 1,309 | 1,222 | – | |
| – | – | – | – | |
| 13.6% | 8.1% | 10.3% | 11.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 184 | 123 | 112 | 91 | |
| – | – | – | – | |
| 184 | 123 | 112 | 91 | |
| Dividends paid | 157 | 90 | 175 | 110 |
| 50 | 17 | 106 | 51 | |
| – | – | – | – |
Valuation
- 8.6×
- –
- –
- 0.9×
- 8.4×
- 12.2×
- –
- 8.2%
- 11.7%
- 9.9%
Profitability
- –
- –
- 98.4%
- –
- –
- –
- –
- –
- –
- –
Growth
- −10.5%
- –
- –
- –
- −3.8%
Financial health
- –
- –
- –
- –
- –
- –
- –
9.9%of the share price, paid each year
On $1,000 invested$99a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
85.0% of its profit
Room to growStretchedMore than it earns: 121.2%
News
The big winners of the tech wreck are biopharma stocksMarketWatch · Oct 30, 2026Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregationSeeking Alpha · Sep 25, 2026Chinese biopharma stocks jump as U.S. weighs keeping door open to drug dealsCNBC · Sep 21, 2026Moderna’s cancer-vaccine breakthrough drives broad biopharma stock rallyMarketWatch · Aug 19, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about BioPharma Credit Ord
Is BioPharma Credit Ord a good stock to buy?
A strong, very profitable business, and the price looks low. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioPharma Credit Ord AI analysis
Does BioPharma Credit Ord pay a dividend?
Yes. At today's price the dividend is 9.9% a year, about 85% of its yearly profit. In 2025 it paid out $110 million in dividends.
How has BioPharma Credit Ord stock done over the past year?
Up 7.6% over the past twelve months, to $0.99. It traded between $0.89 and $0.99, close to its high.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.